WEE1 (IC50 = 24 nM); Myt1 (IC50 = 72 nM); Chk1 (IC50 = 3.433 μM)

在七分之七的癌细胞系中，PD0166285 (0.5 μM) 显着抑制辐射诱导的 Cdc2 Tyr-15 和 Thr-14 磷酸化[1]。在 p53 突变体 HT29 细胞和 E6 转染、p53 缺失的卵巢癌细胞系 PA-1 中，PD0166285 使辐射诱导的细胞杀伤变得敏感；然而，在 p53 野生型 PA-1 细胞中，这种效应不太明显。 PD0166285 可逆转放射诱导的 G2 期停滞，有丝分裂细胞群显着增加[1]。 PD0166285的敏感性增强比为1.23，作为放射增敏剂，使细胞对辐射引起的细胞死亡更加敏感[1]。

---

许多癌症细胞缺乏功能性p53提供了治疗靶点。预计缺乏p53的细胞不会表现出G（1）检查点，并且将依赖于G（2）检查点在经历有丝分裂之前允许DNA修复。我们假设G（2）检查点消除剂可以通过去除保护这些细胞免受DNA损伤过早有丝分裂的唯一检查点，优先杀死p53不活跃的癌症细胞。由于Wee1激酶通过其对Cdc2的抑制性磷酸化在维持G（2）阻滞中起着至关重要的作用，我们开发了一种高通量大规模筛选方法，并将其用于筛选Wee1抑制剂的化学文库。已鉴定出一类吡啶并嘧啶分子，PD0166285，在纳摩尔浓度下抑制Wee1。在细胞水平上，0.5μMPD0166285在所测试的七个癌症细胞系中的七个细胞系中，显著抑制照射诱导的Tyr-15和Thr-14的Cdc2磷酸化。如生化标志物和荧光激活细胞分选仪分析所示，PD0166285消除了辐射诱导的G（2）阻滞，并显著增加了有丝分裂细胞群。在生物学上，PD0166285充当放射增敏剂，使细胞对辐射诱导的细胞死亡敏感，如标准克隆形成试验所示，敏感性增强率为1.23。这种放射增敏活性是p53依赖性的，在p53失活细胞中具有更高的疗效。因此，G（2）检查点消除剂代表了一类新型抗癌药物，通过诱导过早有丝分裂来增强传统癌症治疗的细胞杀伤。[1]

---

PD0166285在体外由P-糖蛋白转运，但不由BCRP转运[2]
研究PD0166285易位的CETA在体外显示了P-gp的转运活性，但没有BCRP的转运活性。在所有表达BCRP的细胞系中，均未观察到易位（图3）。与BCRP相反，发现表达Abcb1a和ABCB1的细胞系都能运输PD0166285，而亲本猪细胞系则不能。同样，在P-gp抑制剂zosuquidar存在的情况下，易位的丧失进一步证实了P-gp是观察到的PD0166285转运的原因。

P-gp，而非BCRP，限制了体内PD0166285的脑渗透[2]
进行了与上述AZD1775类似的药代动力学实验，研究PD0166285的脑渗透。在这个实验中，Abcb1a/b−/−和Abcb1a/b的脑水平都增加了大约5倍；Abcg2-/-小鼠与野生型小鼠的比较（图4b）。因此，这种效应似乎完全是由P-gp引起的，因为当Abcg2-/-也不存在时，没有观察到PD0166285脑水平进一步升高。脑水平的这些差异也反映在脑血浆比率上，因为血浆水平在所有遗传背景下都是相似的。总之，这些结果表明，PD0166285在体内的脑渗透受P-gp的限制，但不受BCRP的限制。

浓度平衡迁移分析[2]
如前所述，使用500 nM的Wee1抑制剂进行浓度平衡转运分析（CETAs），并使用5μM的zosuquidar或elacridar阻断转运。为了制备CETA样品以供后续HPLC分析，将培养基样品与两倍体积的乙腈混合。离心后，将上清液用水稀释3倍，使用GraceSmart RP18 5μm柱（150×2mm）（Grace，Deerfield，IL）通过与紫外检测器连接的高效液相色谱法（HPLC）测量AZD1775或PD0166285的浓度。使用等度条件在340 nm处检测到AZD1775，其中45%乙腈在0.1%（v/v）甲酸水溶液中以0.2 mL/min的流速输送。PD0166285在360 nm处使用相同的柱检测到，该柱用甲醇和0.1%（v/v）甲酸水溶液梯度洗脱，流速为0.2 mL/min，范围为30%至70%。

蛋白质印迹分析[1]
细胞类型：人和小鼠癌细胞系（HCT116、HT29、DLD-1、HCT8、H460、HeLa、C 26 ）。
测试浓度：0.5 μM。
孵化持续时间：4小时。
实验结果：抑制Cdc2Y15和CdcT14磷酸化。

Animal/Disease Models: Wild-type, Abcg2-/-, Abcb1a/b-/- and Abcb1a/b;Abcg2-/- FVB mice[2].
Doses: 5 mg/kg.
Route of Administration: IV.
Experimental Results: Cmax is about 400 ng/mL. P-gp, but not BCRP, limited the brain penetration of PD0166285.

---

Pharmacokinetic studies [2]
We used wildtype, Abcg2−/−, Abcb1a/b−/− and Abcg2;Abcb1a/b−/− FVB mice. PD0166285 (5 mg/kg) and AZD1775 (20 mg/kg) were administered i.v. in DMSO. Blood was collected by cardiac puncture 1 h after injection under isoflurane anesthesia, followed by brain tissue collection. Plasma was obtained by centrifugation (5 min, 5000 rpm, 4 °C). Brains were weighed and homogenized using a FastPrep®-24 in 1% (w/v) bovine serum albumin in water. All samples were stored at −20 °C until analysis. AZD1775 and PD0166285 were extracted using diethyl ether and AZD8055 was used as internal standard. Organic phases were separated and dried by vacuum. Samples were reconstituted in methanol:water (20:80 v/v) and measured in an LC-MS/MS setup consisting of an Ultimate 3000 LC System and an API 4000 mass spectrometer. Separation was performed on a ZORBAX Extend-C18 column. Mobile phase A (0.1% formic acid in water) and B (methanol) was used in a 5 min gradient from 30 to 95%B maintained for 3 min followed by re-equilibration at 30%B. Multiple reaction monitoring (MRM) ion traces were 501.5 / 442.4 (AZD1775) and 512.2 / 438.9 (PD0166285) and 466.2 / 450.1 (AZD8055).

Pharmacokinetic experiments using wildtype and ABC transport knockout mice sampled for brain and plasma at 1 h after drug administration clearly show that these same transporters are responsible for the very low brain penetration of the Wee1 inhibitors in vivo (Fig. 4). Notably, in the absence of these transporters the brain-plasma ratio of both agents was remarkably high (approximately 25 for AZD1775 and 6 for PD0166285), whereas in wild type mice AZD1775 and PD0166285 could only achieve a brain-plasma ratio of 1.0 and 1.2, respectively.

[1]. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001 Nov 15;61(22):8211-7.

[2]. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors. Invest New Drugs. 2018 Jun;36(3):380-387.

PD-0166285 is a small molecule drug with a maximum clinical trial phase of I.

---

Introduction Wee1 is an important kinase involved in the G2 cell cycle checkpoint and frequently upregulated in intracranial neoplasms such as glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). Two small molecules are available that target Wee1, AZD1775 and PD0166285, and clinical trials with AZD1775 have already been started. Since GBM and DIPG are highly invasive brain tumors, they are at least to some extent protected by the blood-brain barrier (BBB) and its ATP-binding cassette (ABC) efflux transporters. Methods We have here conducted a comprehensive set of in vitro and in vivo experiments to determine to what extent two dominant efflux transporters in the BBB, P-gp (ABCB1) and BCRP (ABCG2), exhibit affinity towards AZD1775 and PD0166285 and restrict their brain penetration. Results Using these studies, we demonstrate that AZD1775 is efficiently transported by both P-gp and BCRP, whereas PD0166285 is only a substrate of P-gp. Nonetheless, the brain penetration of both compounds was severely restricted in vivo, as indicated by a 5-fold (PD0166285) and 25-fold (AZD1775) lower brain-plasma ratio in wild type mice compared to Abcb1a/b;Abcg2-/- mice. Conclusion The brain penetration of these Wee1 inhibitors is severely limited by ABC transporters, which may compromise their clinical efficacy against intracranial neoplasms such as DIPG and GBM. [2]
In summary, targeting Wee1 to treat intracranial neoplasms holds promise since Wee1 is overexpressed in various glioma types and several clinical trials have been started. However, since gliomas are highly invasive and thus to a considerable extent protected by the BBB, using a Wee1 inhibitor with sufficient brain penetration capacity is pivotal to the success of this treatment strategy. We demonstrate that both available Wee1 inhibitors, AZD1775 and PD0166285, are efficient substrates of ABC transporters in the BBB and it is therefore not very likely that they will be able to exhibit efficacy in patients.[2]

C26H28CL3N5O2

548.8918

547.131

C, 53.35; H, 4.99; Cl, 24.22; N, 11.96; O, 5.47

212391-63-4

PD0166285;185039-89-8; 212391-63-4 (HCl); 1933496-20-8 (HCl hydrate)

9916391

Typically exists as solid at room temperature

239-242?C

6.641

72.28

3

6

9

37

719

0

ClC1C([H])=C([H])C([H])=C(C=1C1=C([H])C2=C([H])N=C(N([H])C3C([H])=C([H])C(=C([H])C=3[H])OC([H])([H])C([H])([H])N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H])N=C2N(C([H])([H])[H])C1=O)Cl.Cl[H]

NADLBPWBFGTESN-UHFFFAOYSA-N

InChI=1S/C26H27Cl2N5O2.2ClH/c1-4-33(5-2)13-14-35-19-11-9-18(10-12-19)30-26-29-16-17-15-20(25(34)32(3)24(17)31-26)23-21(27)7-6-8-22(23)28;;/h6-12,15-16H,4-5,13-14H2,1-3H3,(H,29,30,31);2*1H

6-(2,6-dichlorophenyl)-2-[4-[2-(diethylamino)ethoxy]anilino]-8-methylpyrido[2,3-d]pyrimidin-7-one;dihydrochloride

212391-63-4; PD-166285; PD 166285; PD0166285 (dihydrochloride); PD 166285 dihydrochloride; PD 166285 2HCl; 6-(2,6-Dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one dihydrochloride; 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-onedihydrochloride;

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

---

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

---

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

---

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。